Seqens Seqens

X

Find Drugs in Development News & Deals for Iloprost

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

0

Australia

Australia

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Aurlumyn (iloprost) is a prostanoid IP receptor agonist, acts as vasodilator that opens blood vessels and stops blood clotting. It is indicated for the treatment of severe frostbite in adults.


Lead Product(s): Iloprost

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Aurlumyn

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The AURORA study is a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study evaluating the safety and efficacy of intravenous (IV) iloprost in patients with SSc experiencing symptomatic digital ischemic episodes (symptomatic Raynaud's Phenomenon).


Lead Product(s): Iloprost

Therapeutic Area: Immunology Product Name: CIVI030

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

The funding will support the initiative by Danish researchers and researchers from BioPorto A/S, to test if evaIloprost (prostacyclin) can potentially reduce damage to the capillaries and counteract ARDS to increase survival rates in COVID-19 patients.


Lead Product(s): Iloprost

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Innovation Fund Denmark

Deal Size: $0.4 million Upfront Cash: Undisclosed

Deal Type: Funding May 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY